Literature DB >> 7977367

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

J M Whaley1, J Naglich, L Gelbert, Y E Hsia, J M Lamiell, J S Green, D Collins, H P Neumann, J Laidlaw, F P Li.   

Abstract

von Hippel-Lindau (VHL) disease is a hereditary tumor syndrome predisposing to multifocal bilateral renal cell carcinomas (RCCs), pheochromocytomas, and pancreatic tumors, as well as angiomas and hemangioblastomas of the CNS. A candidate gene for VHL was recently identified, which led to the isolation of a partial cDNA clone with extended open reading frame, without significant homology to known genes or obvious functional motifs, except for an acidic pentamer repeat domain. To further characterize the functional domains of the VHL gene and assess its involvement in hereditary and nonhereditary tumors, we performed mutation analyses and studied its expression in normal and tumor tissue. We identified germline mutations in 39% of VHL disease families. Moreover, 33% of sporadic RCCs and all (6/6) sporadic RCC cell lines analyzed showed mutations within the VHL gene. Both germ-line and somatic mutations included deletions, insertions, splice-site mutations, and missense and nonsense mutations, all of which clustered at the 3' end of the corresponding partial VHL cDNA open reading frame, including an alternatively spliced exon 123 nt in length, suggesting functionally important domains encoded by the VHL gene in this region. Over 180 sporadic tumors of other types have shown no detectable base changes within the presumed coding sequence of the VHL gene to date. We conclude that the gene causing VHL has an important and specific role in the etiology of sporadic RCCs, acts as a recessive tumor-suppressor gene, and appears to encode important functional domains within the 3' end of the known open reading frame.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977367      PMCID: PMC1918449     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  40 in total

1.  LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

Authors:  K L MELMON; S W ROSEN
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Von Hippel-Lindau disease in a Newfoundland kindred.

Authors:  J S Green; M I Bowmer; G J Johnson
Journal:  CMAJ       Date:  1986-01-15       Impact factor: 8.262

4.  Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.

Authors:  M A Anderson; J F Gusella
Journal:  In Vitro       Date:  1984-11

5.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

6.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

7.  Cerebellar haemangioblastoma and von Hippel-Lindau disease.

Authors:  S M Huson; P S Harper; M D Hourihan; G Cole; R D Weeks; D A Compston
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

8.  Segregation and linkage analyses of von Hippel Lindau disease among 220 descendants from one kindred.

Authors:  R C Go; J M Lamiell; Y E Hsia; J W Yuen; Y Paik
Journal:  Am J Hum Genet       Date:  1984-01       Impact factor: 11.025

9.  Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma.

Authors:  M A Yoshida; K Ohyashiki; H Ochi; Z Gibas; J E Pontes; G R Prout; R Huben; A A Sandberg
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  51 in total

Review 1.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation.

Authors:  Min Zhang; Jie Wang; Jingjing Jiang; Xiaohui Zhan; Yan Ling; Zhiqiang Lu; Jianming Guo; Xin Gao
Journal:  Endocrine       Date:  2014-07-29       Impact factor: 3.633

Review 3.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 4.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

5.  Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

Authors:  C A Jilg; Hartmut P H Neumann; S Gläsker; O Schäfer; C Leiber; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 6.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

7.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.

Authors:  Youn-Sang Jung; Su-Jin Lee; Min-Ho Yoon; Nam Chul Ha; Bum-Joon Park
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

9.  Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis.

Authors:  Hyun-Jung Cho; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.